Related Experiment Video
Updated: Dec 31, 2025
06:52
Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
Published on: April 30, 2019
18.3K
How to introduce MSC-based therapy for the developing lung safely into clinical care?
Mario Rüdiger1, Haresh Kirpalani2, Robin Steinhorn3
1Saxony Center for Feto-Neonatal Health; Department for Neonatology and Pediatric Intensive Care Medicine, Universitätskinderklinik, Universitätsklinikum Dresden, Center for Regenerative Therapies (CRTD), TU Dresden, Dresden, Germany. Mario.ruediger@uniklinikum-dresden.de.
Pediatric Research
|January 14, 2020
Summary
Mesenchymal stromal cells (MSC) show promise for treating bronchopulmonary dysplasia (BPD) in premature infants. A collaborative approach is needed to advance MSC therapies from research to clinical practice.
Area of Science:
- Neonatal Medicine
- Regenerative Medicine
- Pulmonary Medicine
Background:
- Extreme prematurity increases the risk of bronchopulmonary dysplasia (BPD).
- Severe BPD poses a significant long-term burden on infants, families, and society.
- Current prevention and treatment options for BPD are limited.
Purpose of the Study:
- To summarize findings from a workshop on mesenchymal stromal cell (MSC) therapies for BPD.
- To outline a roadmap for advancing MSC-based interventions from research to clinical application.
- To foster a global, collaborative approach involving key stakeholders.
Main Methods:
- Review of promising preclinical data on MSCs for BPD.
- Discussion of initial human clinical trial safety data for MSCs.
- Consensus building among experts during a dedicated workshop.
Main Results:
- Mesenchymal stromal cells (MSCs) demonstrate promising therapeutic potential in animal models of BPD.
- Early clinical studies indicate that MSC administration is safe in human infants.
- A collaborative, multi-stakeholder approach is essential for clinical translation.
Conclusions:
- Mesenchymal stromal cell (MSC) therapy represents a promising regenerative approach for bronchopulmonary dysplasia (BPD).
- Further collaborative efforts are crucial to expedite the development and implementation of MSC-based treatments for premature infants with BPD.
